US2008070908A1PendingUtilityA1

Compositions including antibiotics and methods for using same

60
Assignee: ALLERGAN INCPriority: Jul 30, 1999Filed: Sep 13, 2007Published: Mar 20, 2008
Est. expiryJul 30, 2019(expired)· nominal 20-yr term from priority
Inventors:Christopher A. MullerElizabeth A. BancroftJanet K. CheethamHarold G. JensenTeresa H. KuanDavid F. PowerKevin D. Skule
A61P 43/00A61K 31/535A61K 9/0048A61K 31/196A61P 29/00A61K 31/5365A61P 31/10A61P 31/04A61P 27/02
60
PatentIndex Score
0
Cited by
0
References
0
Claims

Abstract

Compositions including a quinolone component, such as ofloxacin, having fungistatic activity in the compositions, present in an amount effective as an antibiotic when the composition is placed in a mammalian eye, a NSAID component present in an amount to reduce inflammation or pain when the composition is placed in the eye, and a carrier component in an amount effective to act as a carrier for the quinolone component and NSAID component are provided. Methods of using the present compositions, for example, to resolve microbial infections and/or to reduce inflammation and/or pain in a mammalian eye are included within the scope of the present invention. Methods for treating corneal injuries are also included. In addition, methods for treating ocular infections, for example, corneal infections, are included.

Claims

exact text as granted — not AI-modified
1 . A composition comprising: 
 a quinolone component in an amount effective as an antibiotic when the composition is placed in a mammalian eye;    a bromofenac component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye; and    a carrier component in an amount effective to act as a carrier for the quinolone component and the bromfenac component in the composition, the carrier component being ophthalmically acceptable.    
     
     
         2 . The composition of  claim 1  wherein the quinolone component is an ofloxacin component.  
     
     
         3 . The composition of  claim 1  wherein the quinolone component is a doxifloxacin component.  
     
     
         4 . A sealed container comprising a therapeutically effective dose of a composition comprising a bromfenac component in an amount effective as an antibiotic when the composition is placed in a mammalian eye; 
 a NSAID component in an amount effective to reduce inflammation or pain when the composition is placed in a mammalian eye; and    a carrier component in an amount effective to act as a carrier for the bromfenac component and the NSAID component in the composition, the carrier component being ophthalmically acceptable.    
     
     
         5 . The container of  claim 1  wherein the quinolone component is an ofloxacin component.  
     
     
         6 . The container of  claim 1  wherein the quinolone component is a doxifloxacin component.  
     
     
         7 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 1 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         8 . A method for treating a mammalian eye comprising: 
 administering to the mammalian eye a therapeutically effective amount of the composition of  claim 4 , thereby providing an effective antibiotic in the mammalian eye and reducing inflammation or pain in the mammalian eye.    
     
     
         9 . A method for reducing pain in a mammalian eye comprising: 
 administering to a mammalian eye in need of pain reduction a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a bromfenac component in an amount effective, in combination with the quinolone component, to provide a reduction in pain to the mammalian eye.    
     
     
         10 . The method of  claim 7  wherein the quinolone component is an ofloxacin component.  
     
     
         11 . The method of  claim 7  wherein the quinolone component is an doxifloxacin component.  
     
     
         12 . A method for treating a corneal injury comprising: 
 administering to a mammalian eye having a corneal injury a therapeutically effective amount of a composition comprising a bromfenac component in an amount effective as an antibiotic in the mammalian eye and a NSAID component in an amount effective, in combination with the quinolone component, to provide a reduction in paid caused by the corneal injury.    
     
     
         13 . The method of  claim 12  wherein the quinolone component is an ofloxacin component.  
     
     
         14 . The method of  claim 12  wherein the quinolone component is an doxifloxacin component.  
     
     
         15 . The method of  claim 12  wherein the corneal injury is a corneal ulcer.  
     
     
         16 . A method for treating an ocular infection comprising: 
 administering to a mammalian eye having an infection caused by one or more pathogens a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a bromfenac component in an amount effective to reduce the time needed to eliminate the infection relative to identically administering a similar composition without the NSAID component.    
     
     
         17 . The method of  claim 16  wherein the administering step is effective to inhibit colonization of the one or more pathogens in the mammalian eye.  
     
     
         18 . The method of  claim 17  wherein the mammalian eye includes a surface and the administering step is effective to at least inhibit the one or more pathogens from adhering to the surface.  
     
     
         19 . The method of  claim 17  wherein the ocular infection is a corneal infection.  
     
     
         20 . The method of  claim 18  wherein the administering step is effective to inhibit colonization of the one or more pathogens in the mammalian eye.  
     
     
         21 . The method of  claim 14  wherein the administering step is effective to at least inhibit the one or more pathogens from adhering to a cornea of the eye.  
     
     
         22 . The method of  claim 11  herein the quinolone component is an ofloxacin halogenated quinolone component.  
     
     
         23 . The method of  claim 11  wherein the quinolone component is a doxifloxacin component.  
     
     
         24 . A method for treating an ocular infection comprising: 
 administering to a mammalian eye having an infection caused by one or more pathogens a therapeutically effective amount of a composition comprising a quinolone component in an amount effective as an antibiotic in the mammalian eye and a bromfenac component in an amount effective to inhibit colonization of the one or more pathogens in the mammalian eye.    
     
     
         25 . The method of  claim 24  wherein the administering step is effective to inhibit colonization of the one or more pathogens in the mammalian eye.  
     
     
         26 . The method of  claim 24  wherein the mammalian eye includes a surface and the administering step is effective to at least inhibit the one or more pathogens from adhering to the surface.  
     
     
         27 . The method of  claim 24  wherein the ocular infection is a corneal infection.  
     
     
         28 . The method of  claim 24  wherein the administering step is effective to at least inhibit the one or more pathogens from adhering to a cornea of the eye.  
     
     
         29 . The method of  claim 24  herein the quinolone component is an ofloxacin component.  
     
     
         30 . The method of  claim 24  wherein the quinolone component is a doxifloxacin component.

Join the waitlist — get patent alerts

Track US2008070908A1 — get alerts on status changes and closely related new filings.

We store only your email — no account needed. See our privacy policy.